The study patients: Eighty intensive care patients from twelve hospitals in France admitted January 1997-June 1999. Inclusion criteria: Patients had a clinically identified focus of infection with at least two systemic inflammatory response syndrome (SIRS) criteria and one or more sepsis-induced organ failures within 24 hours before inclusion, plus a Simplified Acute Physiology II score between 35 and 63. Exclusion criteria: Patients who were pregnant, younger than 18 years, in a moribund state, in chronic renal failure or receiving immunosuppressive therapy. Although this was a well-designed, multi-centre, randomised, controlled trial, it suffered from inclusion stagnation and was therefore subjected to interim analysis which found a trend towards increased mortality in the experimental group and prolonged requirement for organ support. This resulted in discontinuation of the study. The pre-study power calculations suggested the need for a sample size of 400 patients to detect a 20% decrease in mortality. The study was therefore, ultimately, greatly underpowered. 2. Do the statistical tests correctly test the results to allow differentiation of statistically significant results? Yes. 3. Are conclusions valid in light of the results? Yes, but within the limitations of an under-powered study. The trial was discontinued prematurely because significant adverse effects were observed in the study group and there was a trend to increased mortality. The authors were able to conclude that the use of early conventional CVVH in sepsis is deleterious and has no measurable impact on plasma cytokine levels. 4. Did results get omitted and why? Yes. Although 80 patients were initially enrolled, only 76 patients were analysed. Two patients did not fulfil criteria for inclusion and two were withdrawn from the protocol group by relatives within 48 hours of inclusion. 5. Did the authors suggest areas of further research? Yes. They suggested that although conventional volume haemofiltration did not limit organ failure in sepsis, high volume
Impact of continuous venovenous haemofiltration on organ failure during the early phase of severe sepsis
The use of 25 mL/kg/hr haemofiltration as adjunctive therapy for sepsis is deleterious.
Level of evidence: 1 -(RCT with a high risk of bias, due mainly to the study being under-powered)
Appraised by: A Smith ultrafiltration therapy in sepsis remains to be investigated. 6. Did they make any recommendations based on the results and were they appropriate? No. 7. Is the study relevant to my clinical practice? Yes.
Conventional CVVH is widely used in intensive care to provide renal replacement therapy and severe sepsis is a major cause of mortality in critically ill patients. This study suggests that the application of CVVH, irrespective of the presence of acute renal failure, as an adjunctive therapy for sepsis causes prolongation of organ failures and delays weaning of ventilation and catecholamines. It also results, paradoxically, in an increased incidence of renal failure. While it has been suggested that haemofiltration may have a role in the modification of plasma cytokine levels in sepsis, this does not occur effectively with conventional CVVH. 8. What level of evidence does this study represent? 1 -(RCT with high risk of bias).
9. What grade of recommendation can I make on this result alone? None. 10.What grade of recommendation can I make when this study is considered along with other available evidence? D. There is no body of evidence demonstrating consistency of results here.
There is a lack of adequately sized randomised controlled trials examining the use of haemofiltration as a possible adjunct for the treatment of sepsis. 11.Should I change my practice because of these results? No.
Current practice does not include administration of conventional CVVH alone as a therapy for severe sepsis. 12.Should I audit my current practice because of these results?
No.
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